IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 244 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,929,819 | -3.7% | 274,122 | +31.0% | 0.01% | -12.5% |
| Q3 2022 | $2,004,000 | +23.3% | 209,187 | +42.1% | 0.01% | +33.3% |
| Q2 2022 | $1,625,000 | -40.1% | 147,227 | -9.6% | 0.01% | -33.3% |
| Q1 2022 | $2,713,000 | -4.7% | 162,939 | +9.2% | 0.01% | +12.5% |
| Q4 2021 | $2,847,000 | -10.8% | 149,157 | +15.3% | 0.01% | -20.0% |
| Q3 2021 | $3,190,000 | +33.0% | 129,378 | +40.3% | 0.01% | +25.0% |
| Q2 2021 | $2,399,000 | +9.7% | 92,188 | +33.4% | 0.01% | 0.0% |
| Q1 2021 | $2,187,000 | -34.0% | 69,083 | -3.3% | 0.01% | -33.3% |
| Q4 2020 | $3,316,000 | +29.9% | 71,464 | -7.8% | 0.01% | +20.0% |
| Q3 2020 | $2,553,000 | +35.3% | 77,538 | +12.8% | 0.01% | +25.0% |
| Q2 2020 | $1,887,000 | -37.3% | 68,746 | -31.6% | 0.01% | -46.7% |
| Q1 2020 | $3,011,000 | +8.2% | 100,571 | 0.0% | 0.02% | +50.0% |
| Q4 2019 | $2,784,000 | +59.0% | 100,571 | +4.5% | 0.01% | +42.9% |
| Q3 2019 | $1,751,000 | – | 96,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MHR Fund Management | 11,997,103 | $84,459,605 | 11.88% |
| MPM BioImpact LLC | 2,950,118 | $20,768,831 | 4.18% |
| Perceptive Advisors | 14,036,410 | $98,816,326 | 2.86% |
| Velan Capital Investment Management LP | 240,000 | $1,689,600 | 1.57% |
| Parametrica Management Ltd | 96,500 | $679,360 | 1.31% |
| Boxer Capital, LLC | 3,705,133 | $26,084 | 1.21% |
| Soleus Capital Management, L.P. | 1,239,777 | $8,728,030 | 0.97% |
| Opaleye Management Inc. | 421,000 | $2,963,840 | 0.71% |
| 683 Capital Management, LLC | 1,400,000 | $9,856,000 | 0.71% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,758,759 | $12,381,665 | 0.70% |